DETAILED NOTES ON AS1842856

Probable predictive biomarkers for tumor reaction to mTOR inhibitors, as are already described in glioblastoma, breast and prostate cancer cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Consequently, this knowledge relies on preclinical assays, depending on in vitro cultured tumor cell lines, which counsel